	Enrolment	Baseline	Follow-up												Close-out
Timepoint in months	-1	0	3	6	9	12	15	18	21	24	27	30	33	…	51	36-54
Eligibility screening	x															
Informed consent	x															
Open label colchicine	←	→														
Allocation		x														
Colchicine or placebo		←														→
Sociodemographics																
Age	x															
Sex	x															
Ethnicity	x															
Education level	x															
Employment	x															
Profession	x															
Smoking	x															
Alcohol	x															
Height	x															
Weight	x					x				x				x		x
Waist circumference	x					x				x				x		x
Disease characteristics																
Index joint	x															
Affected joints	x															
Duration of complaints	x															
Joint replacement			x	x	x	x	x	x	x	x	x	x	x	x	x	x
New OA diagnosis						x				x				x		x
Comorbidities	x	x				x				x				x		x
Cardiovascular events		x				x				x				x		x
Questionnaires																
Pain medication			x		x		x		x		x		x		x	
MARS-5		x		x		x		x		x		x		x		x
NRS pain	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
WOMAC		x		x		x		x		x		x		x		x
EQ-5D-5L		x		x		x		x		x		x		x		x
iPCQ		x		x		x		x		x		x		x		x
iMCQ		x		x		x		x		x		x		x		x
Pill count		x				x				x				x		x
X-ray*		x														x
Blood sampling	x	x				x										x

Hospital visits are indicated in blue and tele contact moments are indicated in yellow. Since the study end date is approximately the same for all patients and the inclusion period is planned to last 1.5 years, the trial duration for an individual patient ranges between 3 and 4.5 years depending on the time of inclusion. *If not made in the past 6 months